Abciximab
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stroke
Conditions
Stroke, Stenosis
Trial Timeline
Apr 1, 2004 → May 1, 2005
NCT ID
NCT00126139About Abciximab
Abciximab is a phase 3 stage product being developed by Eli Lilly for Stroke. The current trial status is terminated. This product is registered under clinical trial identifier NCT00126139. Target conditions include Stroke, Stenosis.
What happened to similar drugs?
7 of 20 similar drugs in Stroke were approved
Approved (7) Terminated (5) Active (10)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00178451 | Phase 1/2 | Withdrawn |
| NCT00440895 | Approved | Completed |
| NCT00440778 | Approved | Completed |
| NCT00420030 | Approved | Completed |
| NCT00354406 | Approved | Completed |
| NCT00167765 | Phase 3 | Terminated |
| NCT00126139 | Phase 3 | Terminated |
| NCT00073372 | Phase 3 | Terminated |
| NCT00169819 | Approved | Completed |
Competing Products
20 competing products in Stroke